Senti Biosciences Holdings, Inc.

SNTI Nasdaq SEC CIK 1854270
Follow Senti Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $19K
Net income −$11.6M +36.1% vs same quarter last year
EPS, diluted −$0.37 +46.4% vs same quarter last year
Operating cash flow −$6.7M +28.8% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$22K
$16K
$17K
$19K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0$20MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$22K−$61.4M
FY24$0−$52.8M
FY23$2M−$71.1M
FY22$3.3M−$58.2M
FY21$2.3M−$55.3M
FY20--
MarginsShare of revenue
  • Operating margin
  • Net margin
−400000%−300000%−200000%−100000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−312631.8%−279263.6%
FY24--
FY23−4687.9%−3592.4%
FY22−1889.3%−1771.5%
FY21−1765.4%−2414.6%
FY20--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$43.6M
FY24−$41.4M
FY23−$64.4M
FY22−$76.3M
FY21−$40.2M
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Senti Biosciences
  • Healthcare median
−300000%−200000%−100000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearSenti BiosciencesHealthcare median
FY25−279263.6%−30.6%
FY24-−47%
FY23−3592.4%−58%
FY22−1771.5%−80.4%
FY21−2414.6%−71.9%
FY20-−62.2%